We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Point-of-Care Device Simultaneously Detects Bacterial Growth and Tests Antibiotic Susceptibility

By LabMedica International staff writers
Posted on 02 Mar 2020
Print article
Image: Schematic of the laser fabricated three-layer paper device for bacteria (Photo courtesy of University of Southampton)
Image: Schematic of the laser fabricated three-layer paper device for bacteria (Photo courtesy of University of Southampton)
A novel paper-based point-of-care device that combines detection of pathogenic bacteria with determination of antibiotic susceptibility is expected to reduce the number of unnecessary antibiotic prescriptions and aid in the on-going struggle to prevent development of antibiotic resistance.

Antimicrobial resistance (AMR) has been identified by the World Health Organization as a global threat that currently claims at least 25,000 deaths each year in Europe and 700,000 world-wide. The number of fatalities attributed to AMR is projected to reach 10 million per year between 2015 and 2050. Therefore, there is an urgent need for low-cost but reliable point-of-care diagnostics for early screening of infections especially in developing countries lacking in health care infrastructure and trained personnel.

To this end, investigators at the University of Southampton (United Kingdom) developed a laser-patterned paper-based device for detection and susceptibility testing of Escherichia coli, the main cause of urinary tract infections, via a simple visually observable color change.

The test device comprises three layers - a top paper layer containing four common antibiotics in confined rectangular areas, an absorbent paper in the middle, and an agar gel-containing base layer, all sealed in a plastic casing.

A test is performed by adding a liquid sample (such as urine) to a small paper tab, which is then covered with tape to prevent drying out or contamination. The sample diffuses across the middle paper layer and through the four rectangles containing the test antibiotics (amoxicillin, ciprofloxacin, gentamicin and nitrofurantoin). If bacteria are present in the sample, their growth will cause the paper to turn blue. If the bacteria are susceptible to one (or more) of the antibiotics, a clear patch caused by growth inhibition will be seen around the corresponding rectangle.

In comparison studies using artificial urine spiked with E.coli, the new paper-based device gave results similar to those obtained by growth in petri dishes with agar gel.

"By enabling doctors to quickly determine if an infection is caused by bacteria, and if the bacteria are resistant to four common antibiotics, this device could cut down on unnecessary antibiotic prescriptions and help fight the growing threat of antibiotic resistance," said senior author Dr. Collin Sones, associate professor of optoelectronics research at the University of Southampton.

The device for simultaneous detection and antibiotic-resistance testing of bacterial infections was described in the March 15, 2020, online edition of the journal Biosensors and Bioelectronics.

Related Links:
University of Southampton

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.